Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression (Q57142667)

Expert Opinion on Therapeutic Targets

Europe PubMed Central

title

Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression (English)

0 references

1 reference

1 reference

Elisabeth Jones

1

0 references

Hong Pu

series ordinal

2

0 references

Natasha Kyprianou

series ordinal

3

0 references

language of work or name

English

0 references

publication date

February 2009

0 references

published in

0 references

volume

13

0 references

issue

2

0 references

page(s)

227-34

0 references

cites work

Barriers to access prevention of mother-to-child transmission for HIV positive women in a well-resourced setting in Vietnam.

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Targeting vasculature in urologic tumors: mechanistic and therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Role of TGF-beta in immune-evasion of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

The TGFBeta pathway as a therapeutic target in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Non-Smad TGF-beta signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transcriptional regulation of the TGF-beta1 promoter by androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Role of transforming growth factor-beta1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGFbeta1-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transforming growth factor-beta in cancer and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

New highlights on stroma-epithelial interactions in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Differentiation plasticity regulated by TGF-beta family proteins in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGF-beta and BMP7 interactions in tumour progression and bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Targeting TGFbeta signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Novel oncogenic protein kinase inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

TGF-beta antagonists: why suppress a tumor suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Adeno-associated virus vectors for short hairpin RNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Use of adeno-associated viral vector for delivery of small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696

Androgen receptor is a tumor suppressor and proliferator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220802705696